Evidence map›Paper›PMID 32782524›Full record

ReviewOncology letters2020

Cervical cancer in low and middle-income countries.

Rodney Hull, Mzwandile Mbele, Tshepiso Makhafola, Chindo Hicks, Shao-Ming Wang, Rui Manuel Reis, Ravi Mehrotra, Zilungile Mkhize-Kwitshana, Gibson Kibiki, David O Bates and 1 more

2 registry-linked trialsOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 299 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
299citing papers in PubMed, 10 pooled it
27.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06810427 naactive not recruitingnot on this mapstarted 2025, after this paper: background citation

A Novel, Low-Cost, Handheld 3D Imaging System for Improved Screening for Cervical Neoplasia in Resource-Limited Settings

TypeinterventionalSponsorCarilion ClinicRan2025 to 2026Enrolled18ConditionsCervical Intraepithelial NeoplasiaArmsCervImage device
NCT06815939 narecruitingnot on this mapstarted 2025, after this paper: background citation

Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer: Automated Visual Evaluation

TypeinterventionalSponsorDL AnalyticsRan2025 to 2026Enrolled10,000ConditionsHuman Papillomavirus (HPV), Cervical Intraepithelial Neoplasia, Uterine Cervical Neoplasms, Cervical CancersArmsHPV Test, EVA System, Visual Inspection with Acetic Acid (VIA), Automated Visual Evaluation (AVE), Image Capture with Mobile Phone
3 · Its place in the literature

Who cites it

299 citing papers in PubMed, 10 syntheses or guidelines pooled it, 508 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

239 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 6 countries.

Rodney HullSA-MRC/UP Precision Prevention and Novel Drug Targets for HIV-Associated Cancers Extramural Unit, Pan African Cancer Research Institute, Faculty of Health Sciences, University of Pretoria, Hatfield 0028, South Africa.
Mzwandile MbeleSA-MRC/UP Precision Prevention and Novel Drug Targets for HIV-Associated Cancers Extramural Unit, Pan African Cancer Research Institute, Faculty of Health Sciences, University of Pretoria, Hatfield 0028, South Africa.
Tshepiso MakhafolaSA-MRC/UP Precision Prevention and Novel Drug Targets for HIV-Associated Cancers Extramural Unit, Pan African Cancer Research Institute, Faculty of Health Sciences, University of Pretoria, Hatfield 0028, South Africa.
Chindo HicksBioinformatics and Genomics Centre, School of Medicine, Department of Genetics, Louisiana State University, New Orleans, LA 70112, USA.
Shao-Ming WangNational Cancer Centre, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China.
Rui Manuel ReisMolecular Oncology Research Centre, Barretos Cancer Hospital, Sao Paulo 14784-400, Brazil.
Ravi MehrotraIndian Council of Medical Research, New Delhi, Delhi 110029, India.
Zilungile Mkhize-KwitshanaSchool of Medicine, University of Kwazulu-Natal, Durban, Kwazulu-Natal 4013, South Africa.
Gibson KibikiEast African Health Research Commission, East African Community, Bujumbura, Bujumbura Mairie 350, Burundi.
David O BatesQueen's Medical Centre, University of Nottingham, Nottingham, Nottinghamshire NG7 2UH, UK.
Zodwa DlaminiSA-MRC/UP Precision Prevention and Novel Drug Targets for HIV-Associated Cancers Extramural Unit, Pan African Cancer Research Institute, Faculty of Health Sciences, University of Pretoria, Hatfield 0028, South Africa.
South African Medical Research Council · ZAUniversity of Pretoria · ZAChinese Academy of Medical Sciences & Peking Union Medical College · CNHospital de Câncer de Barretos · BRIndian Council of Medical Research · INLouisiana State University · USUniversity of KwaZulu-Natal · ZAUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is a malignant tumour that occurs in the cervix and is classified into two histological types, adenocarcinoma and squamous cell carcinoma (SCC); SCC is more common and accounts for 70% of all cases. In 2018 there were ~569,000 new cases of cervical cancer diagnosed worldwide and ~311,000 deaths were attributed to cervical cancer. Of these, between 84 and 90% occurred in low- and middle-income countries (LMICs) such as South Africa, India, China and Brazil. The most common cause of cervical cancer is persistent infection caused by the sexually transmitted human papilloma virus. Other factors that contribute to the incidence of cervical cancer include geography, traditional practices and beliefs, the screening levels, socioeconomic status, healthcare access, public awareness, use of oral contraceptives, smoking and co-infection with HIV. An estimated 11 million women from LMICs will be diagnosed with cervical cancer in the next 10-20 years. The aim of this review was to explore various types of genetic and epigenetic factors that influence the development, progression or suppression of cervical cancer.

Indexed as

Brazilcervical cancerIndiamiRNASouth AfricaTanzania

Identifiers

PMID32782524
PMCPMC7400218
OpenAlexW3036318564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.